Aspirin-free antiplatelet strategies after percutaneous coronary interventions

Piera Capranzano,David Moliterno,Davide Capodanno
DOI: https://doi.org/10.1093/eurheartj/ehad876
IF: 39.3
2024-01-21
European Heart Journal
Abstract:Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y 12 receptor inhibitor is the standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several trials have challenged guideline-recommended DAPT after PCI by testing the relative clinical effect of an aspirin-free antiplatelet approach—consisting of P2Y 12 inhibitor monotherapy after a short course (mostly 1–3 months) of DAPT—among patients undergoing PCI without a concomitant indication for oral anticoagulation (OAC). Overall, these studies have shown P2Y 12 inhibitor monotherapy after short DAPT to be associated with a significant reduction in the risk of bleeding without an increase in thrombotic or ischaemic events compared with continued DAPT. Moreover, the effects of the P2Y 12 inhibitor monotherapy without prior DAPT or following a very short course of DAPT after PCI are being investigated in emerging studies, of which one has recently reported unfavourable efficacy results associated with the aspirin-free approach compared with conventional DAPT. Finally, P2Y 12 inhibitor alone has been compared with aspirin alone as chronic therapy after DAPT discontinuation, thus challenging the historical role of aspirin as a standard of care for secondary prevention following PCI. A thorough understanding of study designs, populations, treatments, results, and limitations of trials testing P2Y 12 inhibitor monotherapy vs. DAPT or vs. aspirin is required to consider adopting this treatment in clinical practice. This review addresses the use of aspirin-free antiplatelet strategies among patients undergoing PCI without a concomitant indication for OAC, providing an overview of clinical evidence, guideline indications, practical implications, ongoing issues, and future perspectives. Studies on aspirin-free antiplatelet approaches after percutaneous coronary intervention (PCI) can be divided into two groups: (i) those comparing P2Y 12 inhibitor monotherapy vs. dual antiplatelet therapy (DAPT) after PCI in patients with and without concomitant indication for oral anticoagulation (OAC) and (ii) those comparing P2Y 12 inhibitor monotherapy vs. aspirin monotherapy after DAPT discontinuation or in patients with established coronary artery disease (CAD), including prior PCI patients. Among studies of the first group, one recent study assessing an aspirin-free treatment since the PCI time has shown that monotherapy with low-dose prasugrel vs. DAPT was associated with increased 30-day thrombotic events; other studies assessing the P2Y 12 inhibitor monotherapy after very short DAPT limited to the peri-PCI time are ongoing. The other studies of the first group have shown that P2Y 12 inhibitor monotherapy following a short course of DAPT after PCI (<1 month in one study and 1–3 months in most studies) or combined with OAC was associated with decreased bleeding and similar overall ischaemic events compared with conventional DAPT. Overall studies of the second group have shown that P2Y 12 inhibitor monotherapy (clopidogrel or ticagrelor) vs. aspirin was associated with similar bleeding, reduced myocardial infarction (MI) with a number needed to treat (NNT) > 100 across studies, and comparable mortality. ST, stent thrombosis.
cardiac & cardiovascular systems
What problem does this paper attempt to address?